Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rezdiffra
Pharma
Madrigal's MASH drug Rezdiffra posts 35% sales increase in Q3
Madrigal’s MASH drug Rezdiffra generated sales of $287 million in the third quarter and is now annualizing sales at more than $1 billion.
Kevin Dunleavy
Nov 5, 2025 12:02pm
Big Pharma bets big on MASH with a new combo playbook
Oct 17, 2025 9:30am
Novo's Wegovy in line for a 'swift' adoption in MASH: Spherix
Aug 29, 2025 11:40am
With key FDA nod in MASH, Novo's Wegovy scores 3rd indication
Aug 18, 2025 10:08am
ExCellThera's novel blood cancer cell therapy gains CHMP nod
Jun 20, 2025 11:55am
Madrigal's first-ever MASH drug beats sales projections again
May 2, 2025 11:00am
